Clinical Trial Update: Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084) [Phase 4]

View source ↗

Summary

This Phase 4 study evaluating long-term hepatitis A and B antibody persistence in healthy adults previously primed with Twinrix has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A
• Hepatitis B

Drugs mentioned

• Twinrix (Hepatitis A and B vaccine, combined)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Hepatitis A | Phase 4 | Status: WITHDRAWN